

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S  
Form 6-K  
April 08, 2008

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 6-K  
-----

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

April 8, 2008

-----  
NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

NOVO ALLE  
DK-2880, BAGSVAERD  
DENMARK  
(Address of principal executive offices)

-----  
Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g-32(b): 82-\_\_\_\_\_

TREASURY STOCK

NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME

## Edgar Filing: NOVO NORDISK A S - Form 6-K

On 31 January 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no. 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount of up to DKK 2 billion in the period from 31 January 2008 to 6 August 2008.

Since the announcement as of 31 March 2008, the following transactions have been made under the programme:

	NUMBER OF SHARES	AVERAGE PURCHASE PRICE	TRANSACTION VALUE, DKK
ACCUMULATED, LAST ANNOUNCEMENT	2,007,907		653,392,198
31 Mar 2008	50,000	319.4300	15,971,500
01 April 2008	50,000	321.2750	16,063,750
02 April 2008	50,000	322.6800	16,134,000
03 April 2008	50,000	325.7900	16,289,500
04 April 2008	50,000	327.4200	16,371,000
ACCUMULATED, 2008	2,257,907		734,221,948

With the transactions stated above, Novo Nordisk owns a total of 27,218,090 treasury shares, corresponding to 4.2% of the share capital. The total amount of shares in the company is 646,960,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit [novonordisk.com](http://novonordisk.com).

Further information:

Media:

Outside North America:  
Elin K Hansen  
Tel: (+45) 4442 3450  
[ekh@novonordisk.com](mailto:ekh@novonordisk.com)

Investors:

Outside North America:  
Mads Veggerby Lausten  
Tel: (+45) 4443 7919  
[mlau@novonordisk.com](mailto:mlau@novonordisk.com)

Hans Rommer  
Tel: (+45) 4442 4765  
[hrmm@novonordisk.com](mailto:hrmm@novonordisk.com)

In North America:  
Sean Clements  
Tel: (+1) 609 514 8316  
[secl@novonordisk.com](mailto:secl@novonordisk.com)

In North America:  
Christian Qvist Frandsen  
Tel: (+1) 609 919 7937  
[cqfr@novonordisk.com](mailto:cqfr@novonordisk.com)

Stock Exchange Announcement no 20 / 2008

# Edgar Filing: NOVO NORDISK A S - Form 6-K

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: April 8, 2008

NOVO NORDISK A/S

-----  
Lars Rebien Sorensen,  
President and Chief Executive Officer